Logo image
Activities of available and investigational antifungal agents against rhodotorula species
Journal article   Open access   Peer reviewed

Activities of available and investigational antifungal agents against rhodotorula species

D J Diekema, B Petroelje, S A Messer, R J Hollis and M A Pfaller
Journal of clinical microbiology, Vol.43(1), pp.476-478
01/2005
DOI: 10.1128/JCM.43.1.476-478.2005
PMCID: PMC540164
PMID: 15635020
url
https://doi.org/10.1128/JCM.43.1.476-478.2005View
Published (Version of record) Open Access

Abstract

Rhodotorula species are emerging pathogens in immunocompromised patients. We report the in vitro activities of eight antifungals against 64 Rhodotorula isolates collected in surveillance programs between 1987 and 2003. Rhodotorula strains are resistant in vitro to fluconazole (MIC at which 50% of the isolates tested are inhibited [MIC(50)], >128 microg/ml) and caspofungin (MIC(50), >8 microg/ml). Amphotericin B (MIC(50),1 microg/ml) and flucytosine (MIC(50), 0.12 microg/ml) are both active in vitro, and the new and investigational triazoles all have some in vitro activity, with ravuconazole being the most active (MIC(50), 0.25 microg/ml).
Antifungal Agents - pharmacology Microbial Sensitivity Tests Mycoses - epidemiology Humans Mycoses - microbiology Drug Resistance, Fungal Population Surveillance Rhodotorula - drug effects Rhodotorula - isolation & purification

Details

Metrics

Logo image